Parvez Mantry, MD, shares real-world resmetirom data from AASLD 2026, including GLP-1 combination use and biopsy-sparing monitoring.
|Articles|April 5, 2011
ACC 2011 Interview on Cost Analysis Substituting Dabigatran for Warfarin
Dr. Julie Atay discusses her poster at ACC 2011 on "Cost Analysis of Substituting Dabigatran for Warfarin in an Anticoagulant Management Program."
Advertisement
Advertisement
Related to this article
Michael Mina, MD, PhD, of Invivyd, on measles antibody VMS063, immune amnesia, and what RSV antibody uptake signals for payers.
Advertisement
Advertisement
Trending on AJMC
1
Survodutide Meets CV Safety End Point in SYNCHRONIZE-CVOT
2
FDA Approves First Dual-Targeted Therapy for Advanced HNSCC
3
Pharmacy, Claims Data Show High Resmetirom Persistence in MASH
4
Phase 3 Data Back ALP Normalization as Treatment Goal in PBC
5